Andrew Jackson
Director of Finance/CFO at CALIDI BIOTHERAPEUTICS, INC.
Net worth: 108 $ as of 29/04/2024
Andrew Jackson active positions
Companies | Position | Start | End |
---|---|---|---|
CALIDI BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 29/10/2023 | - |
Career history of Andrew Jackson
Former positions of Andrew Jackson
Companies | Position | Start | End |
---|---|---|---|
ETERNA THERAPEUTICS INC. | Director of Finance/CFO | 30/05/2022 | 03/05/2023 |
CATHETER PRECISION, INC. | Comptroller/Controller/Auditor | 31/03/2018 | 24/05/2022 |
Chief Executive Officer | 11/08/2019 | 29/03/2020 | |
Director of Finance/CFO | 31/03/2018 | 24/05/2022 | |
Corporate Secretary | 31/07/2021 | 24/05/2022 | |
ALTHEADX INC | Director of Finance/CFO | 30/09/2016 | 31/03/2018 |
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Director of Finance/CFO | 31/05/2015 | 29/02/2016 |
Training of Andrew Jackson
University of Minnesota | Undergraduate Degree |
San Diego State University | Graduate Degree |
Statistics
International
United States | 8 |
Operational
Director of Finance/CFO | 5 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
ETERNA THERAPEUTICS INC. | Health Technology |
CALIDI BIOTHERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
Ra Medical Systems, Inc.
Ra Medical Systems, Inc. Medical SpecialtiesHealth Technology Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of vascular immune-mediated inflammatory diseases. Its product, the Destruction of Arteriosclerotic Blockages by laser Radiation Ablation (DABRA) laser and single-use catheter, together referred to as DABRA, is used as a tool in the treatment of peripheral artery disease which commonly occurs in the legs. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Fort Mill, SC. | Health Technology |
AltheaDx, Inc.
AltheaDx, Inc. Pharmaceuticals: MajorHealth Technology AltheaDx, Inc. operates as a commercial stage molecular diagnostics company which specializes in pharmacogenetics. It focuses in depression and anxiety, clinical publications, and IDgenetix testing process. The company was founded by Francois Ferre and Magda Marquet and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Andrew Jackson
- Experience